Bempedoic acid: what prospective uses?

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Elevated low-density lipoprotein cholesterol (LDL-c) remains a primary risk factor for atherosclerotic cardiovascular disease (ASCVD).
• Current lipid-lowering therapies, including statins, ezetimibe, and PCSK9 inhibitors, are often insufficient to achieve target LDL-c levels in high-risk patients.
• Atherosclerotic cardiovascular disease and familial hypercholesterolemia necessitate advanced therapeutic strategies for effective LDL-c reduction.

Purpose of the Study:

• To evaluate the efficacy of bempedoic acid in reducing LDL-c levels.
• To assess the safety profile of bempedoic acid in diverse patient populations.
• To determine the effectiveness of bempedoic acid as an add-on therapy when maximally tolerated statins fail to reach lipid goals.

Main Methods:

• Clinical trials involving patients with ASCVD and/or familial hypercholesterolemia.
• Administration of bempedoic acid to assess its impact on lipid profiles.
• Monitoring of patient outcomes and adverse events to evaluate safety.

Main Results:

• Bempedoic acid demonstrated a significant reduction in LDL-c across various patient groups.
• The treatment was associated with a favorable safety profile.
• Achieved substantial LDL-c lowering in patients who did not reach their goals with existing therapies.

Conclusions:

• Bempedoic acid is an effective therapeutic option for lowering LDL-c in patients with ASCVD and familial hypercholesterolemia.
• Its favorable safety profile makes it a valuable addition to the lipid-lowering armamentarium.
• Bempedoic acid addresses an unmet need for effective treatments when standard therapies are inadequate.